Literature DB >> 23132275

MicroRNA profiling in great saphenous vein tissues of patients with chronic venous insufficiency.

Chaoyi Cui1, Guang Liu, Ying Huang, Xinwu Lu, Min Lu, Xintian Huang, Weimin Li, Mier Jiang.   

Abstract

Chronic venous insufficiency (CVI) is a common disease characterized by structural and functional abnormalities of the venous system. Until recently, the pathogenesis of CVI remains largely unknown. MicroRNAs (miRNAs) are a family of endogenous small non-coding RNAs emerged as post-transcriptional gene repressors and play essential roles in diverse pathological processes including vascular disease. However, their roles in CVI have not been elucidated. In this study, we employed oligonucleotide microarrays to perform a genome-wide miRNAs profiling in the great saphenous vein (GSV) tissues of patients with CVI. Our results revealed a total of 14 miRNAs that are expressed differentially in GSV tissues. Among them nine miRNAs were found significantly up-regulated, while five miRNAs were down-regulated significantly. Real-time RT-PCR verified statistically consistent expression of three selected miRNAs (miR-34a, miR-155 and miR-202) with microarrays analysis. These three miRNAs, which were described as crucial regulators in many biological processes and vascular diseases, might also play important roles in CVI. Functional annotation of target genes of differentially expressed miRNAs via bioinformatics approaches revealed that these predicted targets were significantly enriched and involved in several key signaling pathways important for CVI, including mitogen-activated protein kinase pathways, pathways in cancer, apoptosis, and cell cycle, and p53 signaling pathways. In summary, miRNAs might involve in multiple signaling pathways contributing to the pathological processes of CVI. These data may provide fundamental insights into the molecular basis of CVI, which may aid in designing novel approaches for prevention and treatment of this complex disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132275     DOI: 10.1620/tjem.228.341

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  6 in total

Review 1.  Hemodynamics mediated epigenetic regulators in the pathogenesis of vascular diseases.

Authors:  C L Karthika; S Ahalya; N Radhakrishnan; C C Kartha; S Sumi
Journal:  Mol Cell Biochem       Date:  2020-08-25       Impact factor: 3.396

Review 2.  Molecular Aspects of Wound Healing and the Rise of Venous Leg Ulceration: Omics Approaches to Enhance Knowledge and Aid Diagnostic Discovery.

Authors:  Daniel A Broszczak; Elizabeth R Sydes; Daniel Wallace; Tony J Parker
Journal:  Clin Biochem Rev       Date:  2017-02

3.  miRNA Regulatory Networks Associated with Peripheral Vascular Diseases.

Authors:  Daniel P Zalewski; Karol P Ruszel; Andrzej Stępniewski; Dariusz Gałkowski; Marcin Feldo; Janusz Kocki; Anna Bogucka-Kocka
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

4.  Dysregulations of MicroRNA and Gene Expression in Chronic Venous Disease.

Authors:  Daniel P Zalewski; Karol P Ruszel; Andrzej Stępniewski; Dariusz Gałkowski; Jacek Bogucki; Łukasz Komsta; Przemysław Kołodziej; Paulina Chmiel; Tomasz Zubilewicz; Marcin Feldo; Janusz Kocki; Anna Bogucka-Kocka
Journal:  J Clin Med       Date:  2020-04-25       Impact factor: 4.241

5.  Weighted Gene Co-expression Network Analysis for RNA-Sequencing Data of the Varicose Veins Transcriptome.

Authors:  Jianbin Zhang; Qiangqiang Nie; Chaozeng Si; Cheng Wang; Yang Chen; Weiliang Sun; Lin Pan; Jing Guo; Jie Kong; Yiyao Cui; Feng Wang; Xueqiang Fan; Zhidong Ye; Jianyan Wen; Peng Liu
Journal:  Front Physiol       Date:  2019-03-19       Impact factor: 4.566

6.  microRNA-301a-3p is a potential biomarker in venous ulcers vein and gets involved in endothelial cell dysfunction.

Authors:  Ying Wang; Jingchen Du; Yu Liu; Shuhui Yang; Qingshan Wang
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.